Regenxbio Inc
RB0
Company Profile
Business description
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Contact
9804 Medical Center Drive
RockvilleMD20850
USAT: +1 240 552-8181
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
353
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.70 | 38.30 | 0.45% |
| CAC 40 | 7,888.87 | 53.55 | -0.67% |
| DAX 40 | 23,936.23 | 99.88 | -0.42% |
| Dow JONES (US) | 42,677.24 | 114.83 | -0.27% |
| FTSE 100 | 8,777.69 | 3.43 | -0.04% |
| HKSE | 23,827.78 | 146.30 | 0.62% |
| NASDAQ | 19,142.71 | 72.75 | -0.38% |
| Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
| NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
| S&P 500 | 5,940.46 | 23.14 | -0.39% |
| S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
| SSE Composite Index | 3,387.57 | 7.10 | 0.21% |